Biodexa Pharmaceuticals is a UK pharmaceutical company developing a pipeline of products aimed at rare and orphan diseases, mainly in the area of oncology. Its main program focuses on primary and metastatic cancers of the brain and central nervous system.

The company has developed an experimental drug, known as MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma (rGBM), diffuse midline glioma (DMG) (also known as diffuse intrinsic pontine glioma (DIPG)) and medulloblastoma. 

The reSOLVE clinical trials program is Biodexa’s commitment to resolving unmet medical needs. This is part of our company’s Mission to advance medicines that will provide a brighter future for patients with serious conditions; especially those not fully served by existing treatments. The name "reSOLVE" was inspired by both our Mission, and our MidaSolve™ technology platform. This platform is used to produce solubilized formulations of poorly water-soluble substances, therefore enabling a direct delivery to the site of action. MTX110 was the first product we produced using the MidaSolve™ platform.

MTX110 is a liquid form of a drug known as Panobinostat. Biodexa Pharmaceuticals is using this liquid form to deliver the product directly to the site of the tumor, either in the brain or spinal column. This website provides information about the studies being conducted using MTX110.

About the reSOLVE Clinical Trials